Related Experiment Video
Updated: Mar 12, 2026
Murine Cervical Aortic Transplantation Model using a Modified Non-Suture Cuff Technique
Published on: November 2, 2019
Cardiac allograft vasculopathy: Microvascular arteriolar capillaries ('capioles") and survival
Carlos A Labarrere1, Beate R Jaeger2, Ghassan S Kassab3
1Carlos A. Labarrere, California Medical Innovations Institute, 11107 Roselle Street, Suite 106, San Diego CA 92121, clabarrere@sbcglobal.net.
Insights
Cardiac allograft vasculopathy (CAV) is a serious heart transplant complication. Novel therapies show promise, but identifying risk factors and early biomarkers for CAV remains crucial.
Area of Science:
- Cardiology
- Immunology
- Transplantation Science
Background:
- Cardiac allograft vasculopathy (CAV) is a significant complication following heart transplantation.
- It affects both adult and pediatric recipients, impacting long-term graft survival.
Purpose of the Study:
- To review the risk factors, pathogenesis, and emerging therapies for cardiac allograft vasculopathy.
- To highlight the need for improved risk stratification, early detection biomarkers, and understanding of antibody-mediated rejection in CAV.
Main Methods:
- Review of existing literature on cardiac allograft vasculopathy.
- Analysis of risk factors, including immunological and non-immunological elements.
- Examination of pathological mechanisms, such as endothelial injury and coagulation cascade activation.
- Evaluation of current and novel therapeutic strategies.
Main Results:
- Identified numerous risk factors for CAV, including HLA mismatches, rejection episodes, immunosuppression, metabolic factors, and donor characteristics.
- Described the pathological progression involving endothelial dysfunction, complement activation, and smooth muscle cell proliferation.
- Noted the development of "capioles" as a potential survival advantage.
- Highlighted novel therapies like statins, apheresis, and fibrin peptide B beta15-42.
Conclusions:
- CAV presents complex challenges in heart transplantation.
- Further research is needed to stratify individual risk, develop early biomarkers, and elucidate antibody-mediated rejection mechanisms.
Abstract:
Cardiac allograft vasculopathy (CAV) is a serious complication of heart transplantation in adults and children. Risk factors include human leukocyte antigen mismatches, number and duration of rejection episodes, type of immunosuppression, antibody-mediated rejection, hypertension, hyperlipidemia, obesity, smoking, diabetes, cytomegalovirus infection, mode of donor brain death, donor age and ischemia/reperfusion injury. Endothelial injury and dysfunction in CAV are characterized by changes in adhesion molecules and up-regulation of major histocompatibility class II antigens followed by endothelial activation of complement C4d. Subsequently, activation of the coagulation cascade leads to deposition of fibrin on endothelium followed by proliferation and migration of vascular smooth muscle cells. The development of a special type of microvessels with phenotypic characteristics of arterial capillaries ("capioles") seems to provide a survival advantage for patients with CAV. Novel therapies of CAV include statins, and heparin-induced extracorporeal low-density lipoprotein apheresis. B beta15-42 which is a fibrin peptide has been shown to improve the graft microvasculature and to reduce ischemia/reperfusion-induced damage. Despite these advances, there is a need to identify and stratify individual CAV risk factors, to develop early biomarkers of CAV, and to better decipher the events that lead to antibody-mediated rejection.
